Trial Profile
A Phase 1b, Randomized, Double-Blinded, Dose Escalation, Single Center, Repeat-Dose Safety and Pharmacodynamics Study of Orally Administered Dapansutrile Capsules in Subjects With NYHA II-III Systolic Heart Failure
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Feb 2022
Price :
$35
*
At a glance
- Drugs Dapansutrile (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Olatec Therapeutics
- 15 Feb 2022 According to Olatec Therapeutics Media, results form this study published in the The Journal of the American College of Cardiology (JACC).
- 11 Feb 2021 According to Olatec Therapeutics Media, results published in the Journal of Cardiovascular Pharmacology, the study met its primary objectives showing dapansutrile is safe and well tolerated in patients in all dose groups.
- 11 Feb 2021 Results published in an Olatec Therapeutics Media Release.